Mature B Cells % of Lymphocytes (CD20+)

If you are on a B-cell depleting therapy, considering one, or living with a condition where these immune cells drive disease, this is the number that tells you whether the therapy is doing its job. A standard complete blood count can tell you how many lymphocytes you have in total, but it cannot tell you how many of those are the antibody-producing B cells that drugs like rituximab and ocrelizumab are designed to eliminate.

This test pulls that B-cell fraction out of the lymphocyte pool and reports it as a percentage. It is a research-and-monitoring marker, not a screening test for healthy adults, and the meaning of any single value depends heavily on what is happening in your body and what you are taking.

What This Test Actually Measures

CD20 (a surface protein found mainly on B cells, encoded by the MS4A1 gene) appears as B cells mature in the bone marrow and disappears once they become antibody-secreting plasma cells. By tagging CD20 with a fluorescent antibody and counting cells through a flow cytometer, the lab can report what fraction of your lymphocytes carry this marker.

In deep immune profiling of 114 healthy adults, CD19+CD20+ B cells made up close to all circulating B cells. So in practical terms, this number is a close stand-in for your circulating mature B-cell pool. A small subset of T cells also shows dim CD20 expression, which is one reason the percentage is not a perfect proxy for B cells alone.

Monitoring B-Cell Depleting Therapy

The most concrete use of this test today is tracking how completely a B-cell depleting drug has worked, and how quickly your B cells are coming back. In a French cohort of 192 people with multiple sclerosis on long-term intravenous anti-CD20 therapy, sustained depletion correlated with reduced disease activity. Studies of repopulation kinetics in 839 rituximab-treated patients showed that older age, kidney impairment, and concurrent corticosteroids or azathioprine all prolong B-cell recovery.

If your B-cell percentage rebounds faster than expected after treatment, you may be a candidate for earlier redosing. If it stays suppressed for many months past your dosing schedule, that has implications for infection risk and antibody response to vaccines. Either way, the number gives you a concrete handle on a treatment whose effects are otherwise invisible between flares.

B-Cell Driven Autoimmune Disease

Several autoimmune conditions feature characteristic shifts in the B-cell pool. Deep profiling in primary Sjögren's syndrome found significant alterations in naive versus memory B-cell subsets compared with healthy controls. In children with idiopathic nephrotic syndrome, expansion of class-switched B cells (a subset within the CD20+ pool) tracked with disease relapse after rituximab therapy in a 30-patient analysis.

What this means for you: if you have a B-cell-driven autoimmune condition, your total CD20+ percentage is one piece of the picture. The subset breakdown within that pool can carry additional information, which is why detailed B-cell phenotyping panels exist alongside this simpler measurement.

B-Cell Lymphomas and Leukemias

In B-cell malignancies (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma), the cancer cells themselves usually carry CD20. A study of 325 newly diagnosed follicular and DLBCL patients found low circulating B-lymphocyte counts compared with healthy controls, with possible prognostic implications. CD20 expression intensity on leukemic blasts in 224 children with B-cell precursor acute lymphoblastic leukemia was an independent predictor of relapse-free survival.

A standalone percentage from a flow cytometry panel is not a diagnostic test for lymphoma. Diagnosis requires biopsy, full immunophenotyping panels, and imaging. But when this number looks abnormal in the wrong direction (markedly elevated, or paired with abnormal lymphocyte morphology), it can be the trigger that leads to a more thorough workup.

Reference Ranges

There is no single universally agreed clinical cutpoint for CD20+ mature B cells as a percentage of lymphocytes. The numbers below come from a deep flow-cytometry study of 114 healthy adults, where CD19+CD20+ B cells (essentially all mature B cells) were measured as a fraction of lymphocytes. They are illustrative orientation, not a target. Your lab will likely report slightly different ranges depending on its gating strategy and reference population.

Source: healthy adult ranges based on Feng et al., Annals of Medicine, 2022 (114 adults, deep flow-cytometric immune profiling). Compare your results within the same lab over time for the most meaningful trend.

Tracking Your Trend

A single B-cell percentage is most useful when you have a baseline to compare it against. Lymphocyte subsets can shift transiently with acute illness, vaccination, or even a single hard workout. A study of one bout of aerobic exercise in chronic lymphocytic leukemia found that CD5+CD19+CD20+ B cells were temporarily mobilized into the bloodstream, illustrating how short-term physiology can move the number without changing your underlying immune state.

If you are starting or already on anti-CD20 therapy, a reasonable cadence is to test before treatment, again at the time depletion is expected to be complete (typically within weeks), and then every few months to track repopulation. If you are using this test for general immune profiling, get a baseline now and retest in 6 to 12 months, sooner if your clinical picture changes.

What an Abnormal Result Should Trigger

A value far outside the typical adult range is rarely diagnostic on its own. The next steps depend on the direction of the abnormality and your context. If your percentage is very low and you are not on B-cell depleting therapy, ask about quantifying total immunoglobulins (IgG, IgA, IgM) and consider an immunology consult. If the percentage is markedly high, especially with an elevated absolute lymphocyte count, the workup typically includes peripheral blood smear review, full lymphocyte immunophenotyping, and a hematology referral to evaluate for a lymphoproliferative process.

If you are on rituximab, ocrelizumab, or obinutuzumab and your B cells are recovering faster or slower than your dosing schedule assumes, that is a conversation with your prescribing specialist about timing and interval, not a do-it-yourself adjustment.

When Results Can Be Misleading

• Recent intense exercise: a single hard workout can transiently mobilize CD5+CD19+CD20+ B cells into the circulation. The shift normalizes within hours and does not reflect a sustained change in your immune state.
• Acute infection or recent vaccination: lymphocyte subsets shift during and after immune activation. Wait at least 2 to 4 weeks after an acute illness or vaccine before drawing a baseline you plan to interpret.
• Corticosteroids and other immunosuppressants: medications taken for unrelated conditions can alter lymphocyte trafficking and subset percentages without indicating B-cell disease. Note any current immunosuppressive therapy when interpreting your number.
• Lab-to-lab differences: flow cytometry gating strategies, antibody clones, and reference populations vary across labs. Comparing a value from one lab to a reference range from another can produce misleading conclusions. Track your trend within a single lab whenever possible.